Sinopharm Group (original) (raw)
Sinopharm Group, Txinako sendagai biologiko arloko produktuen enpresa bat da. 2003an sortua, Shanghai hirian egoitza nagusia du.
| Property | Value |
|---|---|
| dbo:abstract | Die Sinopharm Group ist ein chinesisches Pharmaunternehmen. Die Muttergesellschaft der Sinopharm Group war Sinopharm Industrial Investment, ein 51 zu 49-Joint Venture zwischen der staatlichen und der privaten Fosun Pharmaceutical. Die Sinopharm-Gruppe erforscht und entwickelt, produziert, vertreibt und vermarktet Arzneimittel und andere Gesundheitsprodukte. Die Sinopharm Group verwaltet Fabriken, Forschungslabors, Plantagen der traditionellen chinesischen Medizin sowie Marketing- und Vertriebsnetzwerke, die sich über ganz China erstrecken. Seit 2009 ist die H-Aktie des Unternehmens an der Hongkonger Börse notiert. Der Börsengang betrug 16 HK-Dollar je Aktie. Die Tochtergesellschaft der Sinopharm Group, , und fungierten als Gegenstück der A-Aktie. Die A-Aktie der Sinopharm Group selbst war jedoch nicht notiert. Die Sinopharm-Gruppe lag 2017 auf Platz 194, 2020 auf Platz 169 unter den 500 umsatzstärksten Unternehmen weltweit. Sinopharm hat mit BBIBP-CorV und zwei SARS-CoV-2-Impfstoffe entwickelt. Stand Ende März 2021 wurden von diesen Impfstoffen nach firmeneigenen Angaben weltweit 80 Millionen Dosen verabreicht. Im Mai 2021 erhielt der Impfstoff BBIBP-CorV eine Notfallzulassung der Weltgesundheitsorganisation. (de) Sinopharm Group, Txinako sendagai biologiko arloko produktuen enpresa bat da. 2003an sortua, Shanghai hirian egoitza nagusia du. (eu) Sinopharm est un groupe pharmaceutique chinois fondé en 2003. C'est la plus grande entreprise pharmaceutique en Chine, détenue conjointement par la China National Pharmaceutical Group Corporation et Fosun International. Son chiffre d'affaires en 2013 a atteint les 33,2 milliards de dollars US. Ils développent le vaccin BBIBP-CorV, à particules virales inactivées lors de la Pandémie de Covid-19. (fr) Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted. Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. (en) Sinopharm Group Co., Ltd. (國藥控股股份有限公司, «Синофарм Груп» или «Синофарм Холдинг») — одна из крупнейших фармацевтических компаний Китая и Азии; входит в «большую тройку» фармацевтических компаний страны (наряду с China Resources Pharmaceutical Group и Shanghai Pharmaceuticals) и в сотню крупнейших компаний Китая. Основана в 2003 году, штаб-квартира расположена в Шанхае, контрольный пакет принадлежит China National Pharmaceutical Group. Sinopharm Group специализируется на дистрибуции и логистике фармацевтической и медицинской продукции китайских и международных компаний, на розничных продажах лекарств через сеть аптек, на дистрибуции и лизинге медицинского оборудования, на производстве фармацевтической продукции, химических реагентов и лабораторных материалов. Sinopharm Group заняла 829-е место в списке Forbes Global 2000 за 2016 год. (ru) Sinopharm Group Co., Ltd. är ett kinesiskt läkemedelsföretag. Dess huvudägare är Sinopharm Industrial Investment, ett samriskföretag mellan det statliga och det privata . Sinopharm Group forskar om och utvecklar och tillverkar mediciner och vacciner. Företaget är sedan 2009 noterat på Hongkongbörsen. (sv) O Sinopharm Group é uma empresa farmacêutica chinesa. As empresas controladoras do Grupo Sinopharm são a Sinopharm Industrial Investment, uma joint venture do China National Pharmaceutical Group, de propriedade estatal, e a Fosun Pharmaceutical, empresa privada. (pt) 國藥控股股份有限公司（英文名：Sinopharm Group Co., Ltd.，簡稱：“國藥控股”，港交所：1099）是中國國藥集團旗下的核心企業。 (zh) |
| dbo:thumbnail | wiki-commons:Special:FilePath/Sinopharm_Group_logo.png?width=300 |
| dbo:wikiPageID | 21280820 (xsd:integer) |
| dbo:wikiPageLength | 13660 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1117952037 (xsd:integer) |
| dbo:wikiPageWikiLink | dbc:Pharmaceutical_companies_of_China dbr:Hong_Kong_Stock_Exchange dbr:Peru dbr:Pharmaceutical dbr:Pharmaceutical_company dbr:United_Arab_Emirates dbr:JAMA dbr:Public_company dbc:Chinese_brands dbc:Companies_based_in_Shanghai dbr:CoronaVac dbr:Covaxin dbr:Egypt dbr:Morocco dbc:Fosun_International dbr:Bahrain dbr:A-share_(mainland_China) dbr:COVAX dbr:COVID-19_vaccine dbc:Chinese_companies_established_in_2004 dbc:H_shares dbc:Companies_listed_on_the_Hong_Kong_Stock_Exchange dbc:Retail_companies_of_China dbc:Privatization_in_China dbr:Fosun_Pharmaceutical dbr:Pakistan dbr:Forbes_Global_2000 dbr:President_(corporate_title) dbr:Argentina dbc:Government-owned_companies_of_China dbc:Pharmaceutical_companies_established_in_2003 dbr:China_National_Pharmaceutical_Group dbr:Sinopharm dbr:Civilian-run_enterprise dbr:H_shares dbr:Inactivated_vaccine dbr:Initial_public_offering dbr:Shanghai dbr:World_Health_Organization dbr:State-owned_enterprise dbr:Phases_of_clinical_research dbr:Pharmaceutical_industry_in_China dbr:Sinopharm_CNMC |
| dbp:altname | Sinopharm Group (en) |
| dbp:areaServed | China (en) |
| dbp:assets | (en) 1.38267E11 (dbd:renminbi) |
| dbp:assetsYear | 2015 (xsd:integer) |
| dbp:equity | (en) 3.0052E10 (dbd:renminbi) |
| dbp:equityYear | 2015 (xsd:integer) |
| dbp:footnotes | in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards (en) |
| dbp:founder | dbr:China_National_Pharmaceutical_Group |
| dbp:incomeYear | 2015 (xsd:integer) |
| dbp:industry | dbr:Pharmaceutical |
| dbp:isin | CNE100000FN7 (en) |
| dbp:l | Sinopharm Holding (en) Sinopharm Holding Joint-Stock Limited Company (en) |
| dbp:location | Sinopharm Plaza (en) |
| dbp:locationCity | dbr:Shanghai |
| dbp:locationCountry | China (en) |
| dbp:logo | Sinopharm Group logo.png (en) |
| dbp:logoAlt | logo of Sinopharm Group , with bilingual name on the right (en) |
| dbp:logoCaption | logo of Sinopharm Group , with bilingual name on the right (en) |
| dbp:logoSize | 250 (xsd:integer) |
| dbp:name | Sinopharm Group (en) |
| dbp:netIncome | (en) 3.761E9 (dbd:renminbi) |
| dbp:netIncomeYear | 2015 (xsd:integer) |
| dbp:operatingIncome | (en) 9.169E9 (dbd:renminbi) |
| dbp:order | st (en) |
| dbp:owner | Sinopharm Industrial Investment (en) |
| dbp:parent | Sinopharm Industrial Investment (en) |
| dbp:revenue | (en) CNY 227.069 1,000,000,000 (en) |
| dbp:revenueYear | 2015 (xsd:integer) |
| dbp:s | 国控股份有限公司 (en) 国药控股 (en) 国药控股股份有限公司 (en) |
| dbp:subsid | dbr:Sinopharm_CNMC |
| dbp:t | 國控股份有限公司 (en) 國藥控股 (en) 國藥控股股份有限公司 (en) |
| dbp:title | Sinopharm Group Co., Ltd. (en) |
| dbp:type | dbr:Public_company |
| dbp:wikiPageUsesTemplate | dbt:Authority_control dbt:Chinese dbt:Distinguish dbt:Increase dbt:Infobox_company dbt:Main dbt:Official_website dbt:Reflist dbt:Short_description dbt:Ubl dbt:Aligned_table dbt:Hkex dbt:Pharmaceutical_companies_of_China |
| dct:subject | dbc:Pharmaceutical_companies_of_China dbc:Chinese_brands dbc:Companies_based_in_Shanghai dbc:Fosun_International dbc:Chinese_companies_established_in_2004 dbc:H_shares dbc:Companies_listed_on_the_Hong_Kong_Stock_Exchange dbc:Retail_companies_of_China dbc:Privatization_in_China dbc:Government-owned_companies_of_China dbc:Pharmaceutical_companies_established_in_2003 |
| rdf:type | owl:Thing |
| rdfs:comment | Sinopharm Group, Txinako sendagai biologiko arloko produktuen enpresa bat da. 2003an sortua, Shanghai hirian egoitza nagusia du. (eu) Sinopharm est un groupe pharmaceutique chinois fondé en 2003. C'est la plus grande entreprise pharmaceutique en Chine, détenue conjointement par la China National Pharmaceutical Group Corporation et Fosun International. Son chiffre d'affaires en 2013 a atteint les 33,2 milliards de dollars US. Ils développent le vaccin BBIBP-CorV, à particules virales inactivées lors de la Pandémie de Covid-19. (fr) Sinopharm Group Co., Ltd. är ett kinesiskt läkemedelsföretag. Dess huvudägare är Sinopharm Industrial Investment, ett samriskföretag mellan det statliga och det privata . Sinopharm Group forskar om och utvecklar och tillverkar mediciner och vacciner. Företaget är sedan 2009 noterat på Hongkongbörsen. (sv) O Sinopharm Group é uma empresa farmacêutica chinesa. As empresas controladoras do Grupo Sinopharm são a Sinopharm Industrial Investment, uma joint venture do China National Pharmaceutical Group, de propriedade estatal, e a Fosun Pharmaceutical, empresa privada. (pt) 國藥控股股份有限公司（英文名：Sinopharm Group Co., Ltd.，簡稱：“國藥控股”，港交所：1099）是中國國藥集團旗下的核心企業。 (zh) Die Sinopharm Group ist ein chinesisches Pharmaunternehmen. Die Muttergesellschaft der Sinopharm Group war Sinopharm Industrial Investment, ein 51 zu 49-Joint Venture zwischen der staatlichen und der privaten Fosun Pharmaceutical. Die Sinopharm-Gruppe erforscht und entwickelt, produziert, vertreibt und vermarktet Arzneimittel und andere Gesundheitsprodukte. Die Sinopharm Group verwaltet Fabriken, Forschungslabors, Plantagen der traditionellen chinesischen Medizin sowie Marketing- und Vertriebsnetzwerke, die sich über ganz China erstrecken. (de) Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted. (en) Sinopharm Group Co., Ltd. (國藥控股股份有限公司, «Синофарм Груп» или «Синофарм Холдинг») — одна из крупнейших фармацевтических компаний Китая и Азии; входит в «большую тройку» фармацевтических компаний страны (наряду с China Resources Pharmaceutical Group и Shanghai Pharmaceuticals) и в сотню крупнейших компаний Китая. Основана в 2003 году, штаб-квартира расположена в Шанхае, контрольный пакет принадлежит China National Pharmaceutical Group. (ru) |
| rdfs:label | Sinopharm Group (de) Sinopharm Group (eu) Sinopharm (fr) Sinopharm Group (en) Sinopharm Group (ru) Sinopharm Group (pt) Sinopharm Group (sv) 國藥控股 (zh) |
| owl:sameAs | wikidata:Sinopharm Group http://azb.dbpedia.org/resource/سینوفارم dbpedia-de:Sinopharm Group dbpedia-eu:Sinopharm Group dbpedia-fa:Sinopharm Group dbpedia-fr:Sinopharm Group http://hy.dbpedia.org/resource/Sinopharm_Group dbpedia-no:Sinopharm Group dbpedia-pt:Sinopharm Group dbpedia-ru:Sinopharm Group dbpedia-sv:Sinopharm Group dbpedia-zh:Sinopharm Group https://global.dbpedia.org/id/4uf4M |
| prov:wasDerivedFrom | wikipedia-en:Sinopharm_Group?oldid=1117952037&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Sinopharm_Group_logo.png |
| foaf:isPrimaryTopicOf | wikipedia-en:Sinopharm_Group |
| is dbo:wikiPageDisambiguates of | dbr:Sinopharm_(disambiguation) |
| is dbo:wikiPageRedirects of | dbr:Sinopharm_Group_Company dbr:Sinopharm_Group_Company_Limited dbr:Sinopharm_Holding |
| is dbo:wikiPageWikiLink of | dbr:List_of_companies_listed_on_the_Hong_Kong_Stock_Exchange dbr:List_of_companies_of_China dbr:List_of_pharmaceutical_companies dbr:Fundación_Huésped dbr:Sinopharm_(company) dbr:Óscar_Ugarte dbr:Fosun_International dbr:Fosun_Pharma dbr:Pilar_Mazzetti dbr:Sinopharm_(disambiguation) dbr:Pharmaceutical_industry_in_China dbr:Sinopharm_Group_Company dbr:Sinopharm_Group_Company_Limited dbr:Sinopharm_Holding |
| is foaf:primaryTopic of | wikipedia-en:Sinopharm_Group |
